• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail
-
-

2010 Warning Letters

Recently Posted | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996

Warning Letters issued in 2010

 

* Not issued: A close-out letter may issue when, based on FDA’s evaluation, the firm has taken corrective action to address the violations contained in the Warning Letter. This procedure applies to Warning Letters issued on or after September 1, 2009.

* N/A: Not applicable, the Warning Letter was issued prior to September 1, 2009.

Read more about warning and close-out letters

Posted on December 07, 2010

Letter Issue Date Company Name Issuing Office Subject Close Out Date
September 27, 2010 Steris Isomedix Services, Inc. Dallas District Office CGMP/QSR/Medical Devices/Adulterated Not Issued *
September 27, 2010 CVS Pharmacy, Inc. New England District Office New Drug/False Misleading Labeling December 21, 2010
September 27, 2010 Walgreen Company Chicago District Office New Drug/False Misleading Labeling March 21, 2011
September 24, 2010 Rohrer Dairy Farms Llc Philadelphia District Office Illegal Drug Residue Not Issued *
September 24, 2010 Kranenburg Dairy Dallas District Office Illegal Drug Residue Not Issued *
September 23, 2010 Mundt & Associates, Inc. Center for Devices and Radiological Health Electronic Product Radiation Control December 15, 2010
September 22, 2010 Quality Plus Products, Inc. Seattle District Office Seafood HACCP/Adulterated Not Issued *
September 22, 2010 Defibtech, LLC New England District Office CGMP/QSR/Medical Devices/Adulterated February 02, 2012
September 22, 2010 Spineology, Inc. Center for Devices and Radiological Health Investigational Device Exemptions June 28, 2012
September 21, 2010 Rohr Fish, Inc. Cincinnati District Office Seafood HACCP/Insanitary Conditions/Adulterated Not Issued *


 

Contact FDA

301-796-8490
FDA's Office of Critical Path Programs
-
-
-